Meet us at ISPOR 2025
May 13 - 16 | Montreal, QB
Generate evidence on outcomes and cost effectiveness to accelerate regulatory approval and reimbursement
Join the conversation on the future of real-world evidence
Attend our presentation
Visit our booth (#1315)
Explore our research
What’s really happening with GLP-1s? Insights from AI-enabled RWD
May 14, 2025 | 4:00 - 4:30pm ET
For decades, clinical trials and registries have been the primary methods for generating high-quality evidence on drug and device safety, effectiveness, and access. But they are slow, costly, and often limited in scope. Now, EHR data exceeding FDA standards of data quality, data provenance, and audit readiness, is redefining what’s possible, enabling faster, more flexible, and broadly representative real-world evidence. This session will explore how the linking of complete EHR data, closed claims, and emerging genomic data is transforming drug and device research.
Join us to discover how Truveta Data is delivering insights far ahead of postmarket trial data. We’ll explore findings from published studies using Truveta Data to examine GLP-1 utilization trends, comparative effectiveness for weight loss, access barriers, factors influencing discontinuation and reinitiation, and more.
Ryan Ahern, MD, MPH
Chief Medical Officer & co-founder

Research posters

Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention
Injectable cabotegravir offers a promising alternative to daily oral HIV therapy, but adherence is crucial for effectiveness. Using EHR data, Truveta Research examined adherence patterns, identifying factors associated with patients completing or discontinuing treatment for both HIV prevention and treatment.
Join us to explore how real-world evidence can help optimize adherence strategies for long-acting HIV therapies.

Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation
Despite the life-changing potential of GLP-1s for weight loss and diabetes management, discontinuation rates remain high. But why do patients stop therapy? Truveta Research analyzed clinical notes to uncover the real-world reasons behind discontinuation, revealing key differences between patients using GLP-1s for obesity vs. diabetes.
Join us to better understand the factors influencing GLP-1 therapy persistence and access.

EHR trends in first-time ADHD diagnoses and amphetamine prescriptions across age groups
ADHD diagnoses and amphetamine prescriptions have historically been most common in children and young adults. However, new trends are emerging – first-time ADHD diagnoses and amphetamine prescribing rates are rising among adults over 30. Using EHR data, Truveta Research examined how these trends have shifted from 2021 to 2024 and what they might signal for clinical practice and public health.
Join us to explore how ADHD diagnosis and treatment patterns are evolving across age groups.

Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease
In March 2024, the FDA approved semaglutide for cardiovascular risk reduction in patients with obesity. Did this expand access to GLP-1 therapies, or are other barriers still at play? Truveta Research analyzed real-world EHR data to assess changes in prescribing and dispensing patterns following expanded FDA approval.
Join us to see how real-world evidence sheds light on GLP-1 access and adoption trends.
May 14
4:00 - 7:00pm

Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention
Injectable cabotegravir offers a promising alternative to daily oral HIV therapy, but adherence is crucial for effectiveness. Using EHR data, Truveta Research examined adherence patterns, identifying factors associated with patients completing or discontinuing treatment for both HIV prevention and treatment.
Join us to explore how real-world evidence can help optimize adherence strategies for long-acting HIV therapies.
May 15
10:30am - 1:30pm

Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation
Despite the life-changing potential of GLP-1s for weight loss and diabetes management, discontinuation rates remain high. But why do patients stop therapy? Truveta Research analyzed clinical notes to uncover the real-world reasons behind discontinuation, revealing key differences between patients using GLP-1s for obesity vs. diabetes.
Join us to better understand the factors influencing GLP-1 therapy persistence and access
May 15
4:00 - 7:00pm

EHR trends in first-time ADHD diagnoses and amphetamine prescriptions across age group
ADHD diagnoses and amphetamine prescriptions have historically been most common in children and young adults. However, new trends are emerging – first-time ADHD diagnoses and amphetamine prescribing rates are rising among adults over 30. Using EHR data, Truveta Research examined how these trends have shifted from 2021 to 2024 and what they might signal for clinical practice and public health.
Join us to explore how ADHD diagnosis and treatment patterns are evolving across age groups.
May 16
9:00 - 11:30am

Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease
n March 2024, the FDA approved semaglutide for cardiovascular risk reduction in patients with obesity. Did this expand access to GLP-1 therapies, or are other barriers still at play? Truveta Research analyzed real-world EHR data to assess changes in prescribing and dispensing patterns following expanded FDA approval.
Join us to see how real-world evidence sheds light on GLP-1 access and adoption trends.
Visit us at booth #1315
Learn how Truveta Data can help advance evidence generation for any drug, disease, or device at booth #1315.
Talk to our experts about what makes Truveta Data unique, how researchers are using our dataset, and how we can accelerate your organization’s research.
We’ll be serving drinks at the booth on May 14 at 5:00pm. Come by and have one on us.

Meet our team

Terry Meyerson
CEO and co-founder
Terry was responsible for working with the original health system members to form Truveta and has led the company as CEO since its formation. Terry previously enjoyed a 21-year career at Microsoft, leading the development of Windows, Xbox, and the early days of Office 365. As Executive Vice President, serving on the Senior Leadership Team, Terry played a pivotal role in developing the strategy for Microsoft alongside CEO Satya Nadella. Terry excelled at managing large teams at scale, tackling complex software challenges, and driving growth in partnership with a global ecosystem.

Ryan Ahern, MD, MPH
Chief Medical Officer and co-founder

Lisa Gurry
Chief Growth Officer and co-founder
Overseeing product management, design, clinical informatics, research, marketing, and communications, Lisa leads a team focused on aligning product leadership with go-to-market strategies to help the company achieve its growth goals and mission of Saving Lives with Data. During her 23 years at Microsoft, Lisa held a range of leadership roles focused on business strategy, communications, marketing, and operational excellence. She was responsible for building the brands and leading public relations for some of Microsoft’s most important products.

Dr. Michael Simonov, MD
VP of Product Management
Michael is the VP of Product Mangement at Truveta. He’s also an internist and clinical informaticist whose primary career focus has been leveraging electronic health record data for improving human health. At Truveta, he leads the product and clinical informatics teams to ensure Truveta Data and Studio provide highest-quality data to fuel clinical research. Prior to this role, he served as medical information officer for research at the Yale New Haven Health System and a clinical and EHR researcher in the Yale Department of Medicine.

Conor Wyand
Head of Partner Solutions
Conor is the Head of Partner Solutions at Truveta where he leads a team responsible for engaging with potential new life science customers. Prior to joining Truveta in 2021, Conor spent six years in various leadership positions at Optum Life Sciences, working with pharmaceutical and medical device manufacturers across the value chain to generate RWE for therapeutics and devices. Conor graduated from Brown University with a bachelor’s degree in applied mathematics and economics.

Brianna Cartwright, MS
Pricipal Research Analyst
Brianna is driving innovative projects and collaborations in public health. Her recent work has focused on mental health, GLP-1 receptor agonists, the impacts of the pandemic, and other critical and timely public health topics. With a diverse background spanning academia and industry, she excels at harnessing real-world data (RWD) from multiple sources to tackle complex research questions. Brianna holds a master’s degree in mechanical engineering from the University of Washington.

Steve Usatine
Director of Life Sciences Partnerships
Steve is the Director of Life Sciences Partnerships at Truveta and plays a pivotal role in leveraging real-world data solutions for life sciences companies. Before joining Truveta, Steve served as a Senior Director at Clarify Health, where he spearheaded the expansion of their life sciences customer base. Over his extensive career, Steve developed his passion for improving patient health and outcomes with several pharma manufacturers promoting metabolic and rare disease therapies in specialty and hospital settings while collaborating with medical affairs and patient services teams.

Neil Patel
Director of Life Sciences Partnerships
Neil plays a key role in building the company’s presence with some of the top pharmaceutical and biotech companies in the world. Before Truveta, Neil spent over a decade at the intersection of AI and emerging technologies in healthcare with stints at IBM Watson and Komodo Health (Series B:E). At both IBM and Komodo, Neil played a critical role in shaping the respective GTM strategy and pharmaceutical partnerships all the way from drug development to drug commercialization.

Christian Lisowski
Director of Life Sciences Partnerships
Christian leads strategic collaborations with medical device companies to unlock the power of real-world data. At the intersection of innovation and healthcare, Christian works with partners to accelerate clinical evidence generation, support regulatory needs, and drive better patient outcomes through data-driven insights. His role is central to Truveta’s mission of saving lives with data—by helping medical device manufacturers harness de-identified EHR data from a leading consortium of U.S. health systems.
About ISPOR 2025
This must-attend event welcomes all healthcare stakeholders and is directly relevant to researchers and academicians, assessors and regulators, payers and policy makers, the life sciences industry, healthcare providers, and patient engagement organizations. This global scientific event will cover key HEOR and RWE topics.